Watson Ferrlecit
Executive Summary
Sodium ferric gluconate injection covered by Medicare as of Dec. 1 as a first-line treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental EPO therapy. HCFA issued a National Coverage Decision for the agent on April 20 (1"The Pink Sheet" May 22, p. 25)
You may also be interested in...
American Regent Venofer Injectable Iron Approval Expected In Third Quarter
American Regent Labs expects FDA approval of the injectable iron product Venofer during the third quarter of 2000.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials